PE20221869A1 - Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap - Google Patents
Moleculas de union a antigeno biespecificas dirigidas a ox40 y fapInfo
- Publication number
- PE20221869A1 PE20221869A1 PE2022002061A PE2022002061A PE20221869A1 PE 20221869 A1 PE20221869 A1 PE 20221869A1 PE 2022002061 A PE2022002061 A PE 2022002061A PE 2022002061 A PE2022002061 A PE 2022002061A PE 20221869 A1 PE20221869 A1 PE 20221869A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE UNION A ANTIGENO BIESPECIFICA QUE COMPRENDE: A) AL MENOS DOS DOMINIOS DE UNION A ANTIGENO QUE SE UNEN ESPECIFICAMENTE A OX40; B) UN DOMINIO DE UNION A ANTIGENO QUE SE UNE ESPECIFICAMENTE A LA PROTEINA DE ACTIVACION DE FIBROBLASTOS (FAP) QUE COMPRENDE I) UNA REGION VARIABLE DE LA CADENA PESADA (VH FAP) QUE COMPRENDE i) CDR-H1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 3, ii) CDR-H2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 4, SEQ ID NO: 11 Y SEQ ID NO: 12, Y iii) CDR-H3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 5, Y II) UNA REGION VARIABLE DE LA CADENA LIVIANA (VL FAP) QUE COMPRENDE iv) CDR-L1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 6, SEQ ID NO: 13 Y SEQ ID NO: 14, v) CDR-L2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO:7, Y vi) CDR-L3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 8; Y C) UNA REGION FC COMPUESTA DE UNA PRIMERA Y UNA SEGUNDA SUBUNIDAD QUE PUEDEN ASOCIARSE DE FORMA ESTABLE. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20167624 | 2020-04-01 | ||
PCT/EP2021/058435 WO2021198333A1 (en) | 2020-04-01 | 2021-03-31 | Bispecific antigen binding molecules targeting ox40 and fap |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221869A1 true PE20221869A1 (es) | 2022-12-02 |
Family
ID=70154343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002061A PE20221869A1 (es) | 2020-04-01 | 2021-03-31 | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap |
Country Status (17)
Country | Link |
---|---|
US (3) | US11780919B2 (es) |
EP (2) | EP4126946A1 (es) |
JP (2) | JP2023520684A (es) |
KR (1) | KR20220150935A (es) |
CN (2) | CN115362174A (es) |
AR (1) | AR121706A1 (es) |
AU (1) | AU2021247502A1 (es) |
BR (1) | BR112022019531A2 (es) |
CA (1) | CA3169601A1 (es) |
CL (1) | CL2022002647A1 (es) |
CO (1) | CO2022013898A2 (es) |
CR (1) | CR20220479A (es) |
IL (1) | IL294922A (es) |
MX (1) | MX2022012188A (es) |
PE (1) | PE20221869A1 (es) |
TW (1) | TWI810541B (es) |
WO (2) | WO2021198333A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019007267A2 (pt) | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes |
MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
EP3601346A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
CA3113548A1 (en) | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-fap clone 212 |
AU2019410073A1 (en) | 2018-12-21 | 2021-06-10 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
WO2023117834A1 (en) * | 2021-12-20 | 2023-06-29 | F. Hoffmann-La Roche Ag | Agonistic ltbr antibodies and bispecific antibodies comprising them |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
CN1555411A (zh) | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
JP4871126B2 (ja) | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Her2に対する結合親和性を有するポリペプチド |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DK1976880T3 (en) | 2005-12-21 | 2016-09-26 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
HUE036077T2 (hu) | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
TW201321405A (zh) * | 2011-08-17 | 2013-06-01 | Glaxo Group Ltd | 經修飾之蛋白質及肽 |
DK2961771T3 (da) | 2013-02-26 | 2020-03-02 | Roche Glycart Ag | Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA |
BR112016023417A2 (pt) | 2014-03-21 | 2019-04-16 | F. Hoffmann-La Roche Ag | predição in vitro de meia-vida in vivo |
SG11201607969XA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
CN107074933B (zh) | 2014-10-24 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 基于vh-vl域间角的抗体人源化 |
MY191428A (en) | 2014-11-14 | 2022-06-27 | Hoffmann La Roche | Antigen binding molecules comprising a tnf family ligand trimer |
MA40972B1 (fr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 |
CN114751989A (zh) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
MA43019A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps anti-humain cd19 à affinité élevée |
JP7034066B2 (ja) | 2015-10-02 | 2022-03-11 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激tnf受容体に対する二重特異性抗体 |
RU2018116402A (ru) | 2015-10-07 | 2019-11-07 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
CN109071652B (zh) | 2016-05-11 | 2022-09-23 | 豪夫迈·罗氏有限公司 | 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子 |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
TWI829628B (zh) | 2016-12-19 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 與靶向4-1bb (cd137)促效劑併用之組合療法 |
BR112019007267A2 (pt) | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes |
MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
EP3601346A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
BR112019017753A2 (pt) | 2017-04-04 | 2020-04-07 | Hoffmann La Roche | molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica |
WO2018197533A1 (en) | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Antibody selection method |
CN111246884A (zh) | 2017-11-01 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 新颖的含有tnf家族配体三聚体的抗原结合分子 |
PE20210844A1 (es) | 2017-11-01 | 2021-05-10 | Hoffmann La Roche | Contorsbodies 2 + biespecificos |
KR20200084006A (ko) | 2017-11-01 | 2020-07-09 | 에프. 호프만-라 로슈 아게 | 표적화된 ox40 작용제를 사용하는 병용 요법 |
KR20200132913A (ko) | 2018-03-13 | 2020-11-25 | 에프. 호프만-라 로슈 아게 | 4-1bb 작용제와 항-cd20 항체의 치료 조합 |
CN111655731A (zh) | 2018-03-13 | 2020-09-11 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
KR20200144114A (ko) | 2018-04-13 | 2020-12-28 | 에프. 호프만-라 로슈 아게 | 4-1bbl을 포함하는 her-2 표적화 항원 결합 분자 |
CN112424228A (zh) | 2018-07-04 | 2021-02-26 | 豪夫迈·罗氏有限公司 | 新型双特异性激动性4-1bb抗原结合分子 |
WO2020070035A1 (en) * | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules with trivalent binding to cd40 |
CA3113548A1 (en) * | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-fap clone 212 |
EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
WO2020260329A1 (en) | 2019-06-26 | 2020-12-30 | F. Hoffmann-La Roche Ag | Fusion of an antibody binding cea and 4-1bbl |
-
2021
- 2021-03-30 AR ARP210100805A patent/AR121706A1/es unknown
- 2021-03-31 CN CN202180026226.7A patent/CN115362174A/zh active Pending
- 2021-03-31 BR BR112022019531A patent/BR112022019531A2/pt unknown
- 2021-03-31 CR CR20220479A patent/CR20220479A/es unknown
- 2021-03-31 EP EP21714242.1A patent/EP4126946A1/en active Pending
- 2021-03-31 TW TW110111809A patent/TWI810541B/zh active
- 2021-03-31 IL IL294922A patent/IL294922A/en unknown
- 2021-03-31 US US17/218,948 patent/US11780919B2/en active Active
- 2021-03-31 WO PCT/EP2021/058435 patent/WO2021198333A1/en active Application Filing
- 2021-03-31 EP EP21714241.3A patent/EP4126041A1/en active Pending
- 2021-03-31 JP JP2022558398A patent/JP2023520684A/ja active Pending
- 2021-03-31 KR KR1020227034532A patent/KR20220150935A/ko unknown
- 2021-03-31 CN CN202180026217.8A patent/CN115768473A/zh active Pending
- 2021-03-31 AU AU2021247502A patent/AU2021247502A1/en active Pending
- 2021-03-31 JP JP2022558463A patent/JP2023521582A/ja active Pending
- 2021-03-31 CA CA3169601A patent/CA3169601A1/en active Pending
- 2021-03-31 PE PE2022002061A patent/PE20221869A1/es unknown
- 2021-03-31 MX MX2022012188A patent/MX2022012188A/es unknown
- 2021-03-31 WO PCT/EP2021/058439 patent/WO2021198335A1/en unknown
-
2022
- 2022-09-28 CO CONC2022/0013898A patent/CO2022013898A2/es unknown
- 2022-09-28 CL CL2022002647A patent/CL2022002647A1/es unknown
- 2022-09-30 US US17/937,440 patent/US20230227584A1/en active Pending
-
2023
- 2023-08-29 US US18/457,729 patent/US20240117049A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023521582A (ja) | 2023-05-25 |
US20220025046A1 (en) | 2022-01-27 |
TWI810541B (zh) | 2023-08-01 |
CO2022013898A2 (es) | 2022-10-31 |
CR20220479A (es) | 2022-10-26 |
TW202144437A (zh) | 2021-12-01 |
WO2021198335A1 (en) | 2021-10-07 |
JP2023520684A (ja) | 2023-05-18 |
US11780919B2 (en) | 2023-10-10 |
EP4126041A1 (en) | 2023-02-08 |
US20230227584A1 (en) | 2023-07-20 |
AU2021247502A1 (en) | 2022-09-15 |
US20240117049A1 (en) | 2024-04-11 |
CN115768473A (zh) | 2023-03-07 |
CN115362174A (zh) | 2022-11-18 |
EP4126946A1 (en) | 2023-02-08 |
AR121706A1 (es) | 2022-06-29 |
MX2022012188A (es) | 2022-10-27 |
BR112022019531A2 (pt) | 2022-11-16 |
CA3169601A1 (en) | 2021-10-07 |
IL294922A (en) | 2022-09-01 |
CL2022002647A1 (es) | 2023-06-16 |
KR20220150935A (ko) | 2022-11-11 |
WO2021198333A1 (en) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221869A1 (es) | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap | |
PE20191546A1 (es) | Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
ES2523740T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
JP2020037555A5 (es) | ||
RU2017122014A (ru) | Антитела к c10orf54 и их применения | |
JP2018527903A5 (es) | ||
PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
RU2014120154A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
PE20140848A1 (es) | Anticuerpos monoclonales contra la proteina rgma y sus usos | |
RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
PE20130580A1 (es) | Proteinas terapeuticas de union a dll4 | |
PE20080980A1 (es) | Anticuerpos anti-linfotoxina alfa | |
UA108466C2 (en) | Antibody antagonises c-Met | |
PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
PE20220568A1 (es) | Moleculas de union a cd19 y usos de las mismas | |
JP2018515449A5 (es) | ||
PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
RU2010135976A (ru) | Scfv cинтетический аналог вариабельных участков моноклонального антитела 6313/g2 к рецептору ангиотензина ii типа 1 | |
AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco |